Wiley BROS. Aintree Capital LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Wiley BROS. Aintree Capital LLC decreased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,035 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Wiley BROS. Aintree Capital LLC’s holdings in Pfizer were worth $1,232,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of PFE. RB Capital Management LLC lifted its stake in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. raised its holdings in Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares during the period. United Bank raised its holdings in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the period. Ergoteles LLC raised its holdings in Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after acquiring an additional 79,887 shares during the period. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Stock Down 0.7 %

PFE opened at $40.10 on Friday. The stock has a market cap of $225.33 billion, a PE ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32. The business’s fifty day simple moving average is $43.26 and its 200 day simple moving average is $46.03.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. During the same period in the prior year, the business posted $1.08 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PFE shares. SVB Leerink lowered their target price on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a report on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on shares of Pfizer in a report on Tuesday, February 7th. The Goldman Sachs Group raised shares of Pfizer from a “neutral” rating to a “buy” rating and upped their price target for the stock from $47.00 to $60.00 in a report on Tuesday, December 13th. Jefferies Financial Group assumed coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 price target on the stock. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.